Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab

Checkpoint inhibition (CPI) with anti-PD-1/PD-L1 and anti-CTLA-4 antibodies became a standard therapy in a variety of tumour entities. In particular, in malignant melanoma, CPI revolutionised the therapy within a few years. None the less, interventions in the immune system with these inhibitors regularly cause immune-related adverse events (irAE). Common irAEs such as colitis, dermatitis, pneumonitis or hepatitis are well known, and recommendations for their diagnosis and management have been outlined [1 –4].

Source: European Journal of Cancer - February 19, 2018 Category: Cancer & Oncology Authors: Imke Satzger, Philipp Ivanyi, Florian L änger, Hans-Heinrich Kreipe, Katrin Schaper-Gerhardt, Gernot Beutel, Markus Cornberg, Ralf Gutzmer Tags: Letter to the Editor Source Type: research